Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, et al
The first induction study FIGARO UC 301 (NCT03259334) randomized 380 participants in a 2:2:1 ratio to receive ontamalimab 25mg, 75mg, or placebo subcutaneously at weeks 0, 4, and 8, with the primary endpoint of clinical remission at week 12 showing the 75mg dose achieved statistically significant results at 29.8% versus 15.8% placebo while the 25mg dose did not reach significance at 18.5%, along with superior secondary endpoints including endoscopic response, clinical response, and mucosal healing all favoring the 75mg dose (51)
research finds that most people who stop taking treatment typically regain at least some, if not all, of the weight lost and may lose blood sugar and other related benefits
In general, transitions between GLP-1 agonists follow a washout-and-titrate approach
Couse, J